Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,699.38
(
1.01%
)
US TECH 100
24,015.20
(
0.00%
)
Dow Jones
46,946.41
(
0.83%
)
Brent Oil
100.67
(
2.41%
)
Bitcoin
74,312.99
(
-0.71%
)
News Focus
News Focus
Post# of 257250
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122790
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 63998

Thursday, 07/24/2008 12:33:56 PM

Thursday, July 24, 2008 12:33:56 PM

Post# of 257250
NUVO NU172 notes from 2Q08 CC:

CEO Ted Love said NU172 has several benefits vs other anticoagulants for the CABG and dialysis settings: ability to act in stagnant blood, rapid on/off without an antidote, and lack of renal clearance (especially important in dialysis setting).

NU172 is in phase-1b (#msg-29771841).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now